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were log-transformed and correlations were assessed by Pearson’s r2
and by multivariate correlation adjusting for age, gender and BMI.
Results: In the univariate correlation only COMP and CTX-II were cor-
related with Age (r2¼0.16, p¼0.0005, r2¼0.14, p¼0.004), and CTX-II
with age (r2¼0.13, p¼0.005). C3M and CRPM were signiﬁcantly corre-
lated to ESR (r2¼0.12, p¼0.007, r2¼0.23, p<0.0001). CTX-II were sig-
niﬁcantly correlated with WOMAC function and stiffness (r2¼0.17,
p¼0.0003, r2¼0.17, p¼0.0003). There was a gender dependency seen
for WOMAC scores, ESR and CTX-II (p<0.05), as well as a signiﬁcant
correlation between BMI, WOMAC and ESR (p<0.01). The multivariate
regression was adjusted accordingly. C3M and CRPM remained asso-
ciated with ESR (p¼0.043, p<0.0001). CRPM was associated with
WOMAC pain (p¼0.05) and signiﬁcantly associated with WOMAC
stiffness (p¼0.040). CTX-II was signiﬁcantly associated with WOMAC
stiffness (p¼0.003) and function (p¼0.023). In addition, CRPM was
signiﬁcantly higher in patients with clinical signal of synovitis (9.4[9.1-
9.6] versus 11.3[9.8-13.0], p¼0.004). Patients with a high CRPM level
had an odd ratio of 4.2 [1.6-11], p¼0.005, of having clinical signal of
synovitis when adjust for age, gender and BMI.
Conclusions: The aim was to investigate whether biomarkers of con-
nective tissue degradation and inﬂammation as well of cartilage deg-
radation were associated with clinical measures of inﬂammation. The
results show that especially one biomarker, CRPM, was associated with
different measures normally associated with joint inﬂammation. This
suggests that CRPM could be sensitive, non-invasive and objective
marker of joint inﬂammation. This study was funded by the TreatOA
consortium as well as the Danish research foundation.
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N-PROPEPTIDE OF COLLAGEN IIA (PIIANP) AS A MARKER OF
OSTEOARTHRITIS BURDEN
H.N. Daghestani y, J.M. Jordan z, M. Doherty x, A. Wilson k, V.B. Kraus y.
yDuke Univ., Durham, NC, USA; z The Univ. of North Carolina at Chapel
Hill, Chapel Hill, NC, USA; x The Univ. of Nottingham, Nottingham, United
Kingdom; kUniv. Coll. Dublin, Dublin, Ireland
Purpose: Osteoarthritis (OA) is a direct result of cartilage degradation
and its irreversible loss. Cartilage homeostasis relies on the controlled
catabolism ofmatrix proteins such as collagen and the replacementwith
newly synthesized proteins by chondrocytes. Type II collagen is the
major type of collagen in articular cartilage and is synthesized as a pro-
collagen with propeptide domains. In particular, the N-propeptide of
collagen IIA (PIIANP) has been considered a marker for cartilage turn-
over. In fact, serum levels of PIIANPhavebeen reported tobe signiﬁcantly
decreased in patients with knee osteoarthritis and rheumatoid arthritis,
when compared to healthy controls, reﬂecting decreased synthesis of
collagen in patients with arthritis. The goal of this study was to evaluate
PIIANP as a marker of burden of disease in various joints.
Methods: We evaluated 1235 patients from the Genetics of Generalized
Osteoarthritis (GOGO) study. This cohort consisted of 243 Caucasianmen
and 992 Caucasian women, age range 37-92 years (mean 65.4 ± 9.0 SD)and bodymass index (BMI) range 14.9e61.7 kg/m2 (mean 28.8 ± 6.3 SD).
Serum PIIANP was diluted 10-fold and measured using a competitive
enzyme-linked immunosorbent assay (EMD Millipore Corporation, Mis-
souri,USA)witha sensitivity limitof17.2ng/mL.Anyosteophyte (OST)and
joint space narrowing (JSN) or disc space narrowing (DSN) were scored
bilaterally from radiographs and scores were summed by joint site based
on the number of measurable joint faces. The OA burden scores were
normalized to the possiblemaximal scores by joint site as follows: knees 4
JSN, 8 OST; hips 6 JSN, 8 OST; hands 30 JSN, 30 OST; and lumbar spine 5
DSN,10 OST. The PIIANP concentrations were log transformed so that the
data would be normally distributed. Multivariable linear regression
modelswere used to assess the association of serum PIIANPwith OSTand
JSN/DSN burden of knee, hip, spine, and hand radiographic OA. Models
included all joint sites and disease features with backward stepwise
selection of variables. Models were also adjusted for covariates of age,
gender, and BMI; P-values  0.05 were considered signiﬁcant.
Results: Serum PIIANP concentrations measured in the GOGO cohort
ranged between 86.9 - 24023.1 ng/mLwith ameanvalue of 3800.1 ng/mL.
The overall inter-assay coefﬁcient of variation was 9.6% (N ¼ 19 plates).
SerumPIIANPwas not associatedwith age, gender, nor BMI. Radiographic
JSN data were available for 1235 patients, while OST data were available
for 1233participants. The frequencyof radiographicOA ranged froma low
of 24.7% for any hip JSN to a high of 96.4% for any handOST. Serum PIIANP
was negatively associated with knee OST burden (parameter estimate b:
-0.155, P < 0.0001 adjusted for covariates and knee JSN). Serum PIIANP
wasalsonegativelyassociatedwithhip JSN (b: -0.169, P<0.0001, adjusted
for covariates and hip OST). Although serum PIIANP was positively asso-
ciated with both spine DSN (b: 0.183, P < 0.0001, adjusted for covariates)
and spine OST burden (b: 0.204, P: < 0.0001, adjusted for covariates),
serumPIIANPwas positively associatedwith only spineOST burdenwhen
adjusted for DSN (b 0.179, P: < 0.0001, adjusted for covariates). There was
no association between PIIANP and the burden of hand OA.
Conclusions: Serum PIIANP representing collagen synthesis, was lower
in patients with greater burden of hip and knee OA. Conversely, serum
PIIANP was greater in patients with a higher burden of spine OA. These
results are consistent with a prior study that showed that high serum
PIIANP was especially associated with spine disease (facet arthritis and
presence of disc degeneration e lumbar OST not scored) but also hand
radiographic OA. In our study, prior to adjustment for OST, DSN alone
was signiﬁcantly associated with serum PIIANP but OST proved to be
the independent predictor of the biomarker level rather than DSN.
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POLYAMINES IN OSTEOARTHRITIS
F. Saunders, J.S. Greogory, R.J. Barr, R.M. Aspden. Univ. of Aberdeen,
Aberdeen, United Kingdom
Purpose: Polyamines are ubiquitous polycationic molecules found in all
mammalian cells. They are involved in the regulation of cellular pro-
liferation and levels are elevated in tissues undergoing more rapid
proliferation, such as in cancer cells. In early osteoarthritis (OA) there is
increased proliferation as a response to damage repair. Therefore
polyamines could be a useful marker of this increased proliferation and
OA progression. The purpose of this study was to determine whether
there were differences in polyamine concentrations in a cohort of vol-
unteers with various radiographic grades of hip or knee OA.
Methods: Polyamine concentrations were determined by LC-MS/MS
using a benzoyl chloride derivatisation method from plasma samples
(n¼57 knee & n¼30 hip). Kellgren-Lawrence grade (KLG) was assessed
from radiographs by a single clinician. OA severity groups were deter-
mined by KLG groupings (KLG¼0, both knees/hips or KLG¼1 in one
knee/hip & KLG¼0 for contralateral knee/hip; no OA; KLG¼1 in both
knees/hips, mild OA; KLG¼2, moderate OA; KLG¼3-4 severe OA).
Radiographic OA (ROA) was deﬁned as KLG 2. Plasma concentrations
of plasma analytes were tested using one-way ANCOVA, weighted for
OA severity with polynomial contrasts and adjusted for age & BMI.
Analysis of ROA v no ROA was analysed using independent sample t-
tests. All tests were performed using SPSS v22.0.
Results: Our data show that the determination of plasma polyamine
concentrations is reliable with intra-assay variation % RSD calculated to
be 9.6 (Putrescine; PUT), 7.2 (Spermidine; SPD), 8.4 (Spermine; SPM)
and the inter-assay variation was 8.7 (PUT), 7.9 (SPD) & 9.6 (SPM).
Analysis of the polyamines in plasma by two way ANCOVA for joint
affected and OA severity ﬁltered to exclude the no OA group, showed
that there was a statistically signiﬁcant interaction for PUT
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unadjusted P¼0.018 adjusted; Fig 1 a & b). No interactions were
determined for SPD, SPM or the total polyamine concentration. There
was no difference observed between ROA and no ROA for any of the
polyamines or the total polyamine concentration (PUT P¼0.801, SPD
P¼0.838, SPM P¼ 0.853, total polyamine concentration P¼0.795).
Conclusions: This pilot study indicated that measurement of polyamine
concentrations in plasma of volunteers with osteoarthritis is reprodu-
cible. Few studies investigating polyamine concentrations in OA have
been performed previously and ours is the ﬁrst study to utilise plasma
samples to determine systemic plasma concentrations in OA. Our data
suggest that there are a number of different OA phenotypes, particularly
highlighted by the differences between hip and knee OA. Further study
of polyamine concentrations in OA needs to be carried out with larger
numbers of patients.
Figure 1. Analysis of polyamine concentrations in plasma samples from
volunteers with varying degrees of osteoarthritis severity, divided by
affected joint.
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CCL3 AS SERUM BIOMARKER IN PATIENTS WITH KNEE
OSTEOARTHITIS: A CROSS-SECTIONAL STUDY
Z. Zhang, X. Zhao, W. Liao. First afﬁliated Hosp. of Sun Yat-sen Univ,
Guangzhou, China
Purpose: Inﬂammation is widely accepted to be an essential part of
osteoarthritis, chemokines as mediators of chemoattraction (chemo-
taxis) are known to play a pivotal role in this process. However, its role
in osteoarthritis biomarker is rarely reported. The aim of this cross-
sectional study is to explore the ability of chemokines in serum to
identify the degree of knee osteoarthritis.
Methods: There are altogether 284 knee healthy subjects and 338 osteo-
arthritis patients participated in this project between September, 2012 and
December, 2013. According to the inclusion and exclusion criteria, 47 early
and59 later knee osteoarthritis patients and 75 knee healthy subjectswere
ﬁnally enrolled. Samples were collected prior to any treatment. The
promising chemokines, CCL3, CCL4, CXCL1 and CXCL8/ IL8, and four well
studied proinﬂammatory cytokines, IL1b, IL6, TNFa and resistin, were
quantiﬁed using suspension array. Preoperative radiography, magnetic
resonance imaging and arthroscopy ﬁndings were compared with sus-
pensionarray results.And theoutcomeswerepresented ina statisticalway.
Results: In all serum chemokines and cytokines tested, serum CCL3 and
IL8 were the two best predictors of early osteoarthritis occurred (area
under the curve ¼0.769 and 0.765, respectively). Serum CCL3 was
highly speciﬁcity to early knee osteoarthritis, especially to pre-radiog-
raphy patients, whereas serum IL8 showed low speciﬁcity but high
sensitivity. Signiﬁcant difference in serum CXCL1, IL8, CCL3, CCL4 and
resistin were presented among knee OA patients with different KL
grades. Although the difference did not meet statistical signiﬁcance,
elevated CCL3, CCL4 levels in serumwere associated with the severity of
high burden knee osteoarthritis. Additional, test results from suspen-
sion array were corrected well with those from ELISA.Conclusions: Serum IL8 was a promising diagnostic biomarker for early
knee osteoarthritis. And serum CCL4 was suggested can give well
reﬂection on burden of knee osteoarthritis. Serum CCL3, moreover, was
performed excellent in both sides.
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ESTABLISHING A KNEE PRESERVATION REGISTRY TO FOLLOW
PATIENTS WITH DEGENERATIVE JOINT DISEASE
A. Szulc, H. Murphy, C.K. Nathasingh, E. Lee, A. Payne, I. Inneh,
H.-G. Wisniewski, R. Iorio, L. Jazrawi, J. Slover, J. Samuels, E.J. Strauss,
P.A. Band. NYU-Hosp. for Joint Disease, New York, NY, USA
Purpose: The Joint Preservation Registry (JPR) is a prospective, pragmatic,
observational study, designed to identify clinical and biochemical markers
of osteoarthritis (OA) phenotype, status and progression. Because the time
course of degenerative joint disease is highly variable, the optimal treat-
ment for an individual patient is clinically determined by multiple factors,
and highly variable between both clinicians and patients. Few large data
sets are available studying theways that clinicians andpatients handle this
uncertainty, particularlywith respect to the timingof surgical intervention.
To address this gap in knowledge, the JPR was established to follow con-
senting patients who present with knee symptoms to physicians at the
center for musculoskeletal care of a large tertiary care medical center. The
JPR also is intended to evaluate whether synovial ﬂuid biomarkers pre-
viously found to be predictive of radiologic progression and knee replace-
mentovera3-yearperiod, are alsopredictiveofpain scoreprogressionover
shorter time periods, and useful for optimizing treatment pathways.
Methods: Patients presenting with knee-related complaints were
recruited into a Knee Preservation Registry, asked to consent to regular
follow-up by email or phone every 6-12 months, and to allow any bio-
specimens collected during the course of their standard care to be
retained in a bio-repository for future analyses. Participating inves-
tigators included both physicians and surgeons from the divisions of
Sports Medicine, Rheumatology, and Adult Reconstruction. Inclusion
criteria were deliberately broad to enable a diverse patient population,
ranging from recent acute injury to advanced degenerative disease, and
including patients with comorbidities. The registry is observational and
captures demographics, medical history, anthropometrics, diagnosis
codes, treatments, imaging, and patient-reported outcome (PRO), with
much of the data directly retrieved from the medical record. Synovial
ﬂuid (SF) biomarker analysis and PRO score collection at regular follow-
up are the only study-related procedures. Patients will be followed for 5
years from the time of enrollment.
Results: From September 2012 to July 2014, 813 patients (M ¼ 340, F ¼
473) were recruited for the registry. The average age at enrollment was
52.3 years. SF was aspirated from 167 subjects (225 knees, 57 bilateral,
111 unilateral), for a total of 302 unique SF samples in the current bio-
repository which represents 21% of the total population that was
sampled. The same percentage of patients with effusionwas noted to be
the same (21%) among men and women. Distribution of diagnoses,
deﬁned by ICD-9, was 72% for osteoarthritis (OA), 10% for acute injuries,
and 18% for other non-OA complaints. Approximately half of the
enrolled patients have reached the 6-12 month follow-up.
Conclusions: To our knowledge, this is the ﬁrst pragmatic registry for
knee OA patients that are not scheduled for knee replacement. The
information captured by our registry can be used to study disease phe-
notypes as they relate to treatment alternatives, including ethnic, racial,
socioeconomic and gender disparities. Ultimately we hope to establish
evidence-based treatment pathways using a combination of biomarkers,
PRO scores and advanced imaging to customize the treatment of OA to
individual patient needs and preferences, and to assist surgeons in
determining the appropriate timing for joint replacement.
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SEGREGATING OA PATIENTS WITH AND WITHOUT JOINT
INFLAMMATION USING TWO BIOMARKERS OF CONNECTIVE TISSUE
INFLAMMATION
A.-C. Bay-Jensen, I. Byrjalsen, A. Bihlet, K. Musa, B.J. Riis,
C. Christiansen, M.A. Karsdal. Nordic BioSci. A/S, Herlev, Denmark
Purpose: We have recently identiﬁed the presence fragments of CRP,
generatedbymatrixmetalloproteinases (MMPs). C-reactive protein (CRP)
is an acute phase reactant, involved in both acute and chronic inﬂam-
matory diseases. CRP is producedmainly by the liver upon elevated levels
